BioStem Technologies, Inc. (OTC: BSEM) Appoints David Wolfe and Dr. Michael Beckwith to Its Advisory Board

May 27, 2016

OAKLAND PARK, FL--(Marketwired - May 27, 2016) -  BioStem Technologies, Inc. ("BioStem" or the "Company") (OTC PINK: BSEM) today announced the appointment of David Wolfe and Rev. Michael Bernard Beckwith to its Advisory Board. The Advisory Board of the Company provides advice and guidance to the Board of Directors of the Company, but Advisory Board members are not Directors of the Corporation. Mr. Wolfe and Dr. Beckwith are both well-known opinion leaders in their respective fields.


David "Avocado" Wolfe is a leading educator and 22-year promoter of superfoods that impact longevity, and he has consulted for the world's top CEOs, ambassadors, celebrities, athletes, artists (and Moms, of course). He is the co-developer and spokesperson for the NUTRiBULLET™, which is now the nation's #1 selling kitchen appliance. He is also the co-founder of online health magazine and the Founder and President of the non-profit The Fruit Tree Planting Foundation charity (, which has a mission to plant 18 billion fruit, nut, and medicinal trees around the world.


Reverend Michael Beckwith has authored eight books, produced three movies, and co-authored 120 songs. Dr. Beckwith's notoriety climbed through the production of the very successful film The Secret (2006). He was a regular guest of the Oprah Winfrey and Larry King television programs, and his weekly Friday afternoon radio program on the Los Angeles station, KPFK, is hugely popular. Dr. Beckwith's humanitarian efforts have attracted numerous awards including the 1999 Humanitarian Award from the National Conference for Compassion and Justice, the 2001 Gandhi-King-Ikeda Award from Morehouse College, the 2004 Africa Achievement Peace Award, the 2006 Black Aids Institute Hero Award; and in 2009, the Ebony Magazine's 150 Award. In 1999 he was inducted into the Assembly of the Parliament of the World's Religions.


Henry Van Vurst, BioStem's CEO went on to say, "We could not be more pleased to have Michael Beckwith and David Wolfe joining the team. I strongly believe that the addition of these world-renowned thought leaders will further insure BioStem Technologies' mission of being the Global Leader in Anti-Aging and Regenerative Medicine. Both of these individuals bring a sense of enthusiasm and depth of understanding for the overall wellness of people that is imperative at BioStem Technologies."


About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies (OTC PINK: BSEM) is in the business of regenerative medicine and antiaging strategies throughout the United States, Europe, and Mexico. The Company's mission is to conquer the effects of biological aging (and related acute disease), and its strategy is to discover, develop, produce, and deliver the most effective stem cell and wellness products in the world. The Company is comprised of a diverse group of scientists, physicians, and industry visionaries who are creating innovative products for helping customers live their best, feel their best, and be their best. The company operates four strategic business units - BioStem Cell Therapy, BioStem Wellness, BioStem Pharmaceuticals, and BioStem International - providing a diversified line of products and services that include: clinical stem cell therapy, stem cell R&D, state-of-the-art laboratory services, pharmaceuticals, nutraceuticals, cosmeceuticals, API Repackaging, and medical tourism. 



Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "future," "plan" or "planned," "expects," believe" or "projected." These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, intense competition and additional risks factors as discussed in reports filed by the company with OTC Markets.

Share on Facebook
Share on Twitter
Please reload

Featured Posts

BioStem Technologies Releases Third Quarter 2018 Shareholder Update

December 10, 2018

Please reload

Recent Posts
Please reload